A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma
{{output}}
Currently, immune checkpoint inhibitors have been shown to extend the survival of many cancer patients. However, few studies have focused on immune checkpoint inhibition for the treatment of patients with oral squamous cell carcinoma (OSCC). Here, by screening... ...